148 related articles for article (PubMed ID: 34139124)
1. Pharmacological Advantage of SIRT2-Selective versus pan-SIRT1-3 Inhibitors.
Hong JY; Fernandez I; Anmangandla A; Lu X; Bai JJ; Lin H
ACS Chem Biol; 2021 Jul; 16(7):1266-1275. PubMed ID: 34139124
[TBL] [Abstract][Full Text] [Related]
2. Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
Galli U; Mesenzani O; Coppo C; Sorba G; Canonico PL; Tron GC; Genazzani AA
Eur J Med Chem; 2012 Sep; 55():58-66. PubMed ID: 22835719
[TBL] [Abstract][Full Text] [Related]
3. Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT.
Yagci S; Gozelle M; Kaya SG; Ozkan Y; Aksel AB; Bakar-Ates F; Dundar Y; Eren G
Bioorg Med Chem; 2021 Jan; 30():115961. PubMed ID: 33360574
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Selective SIRT2 Inhibitors as Therapeutic Agents in B-Cell Lymphoma and Other Malignancies.
Chowdhury S; Sripathy S; Webster A; Park A; Lao U; Hsu JH; Loe T; Bedalov A; Simon JA
Molecules; 2020 Jan; 25(3):. PubMed ID: 31973227
[TBL] [Abstract][Full Text] [Related]
5. A bicyclic pentapeptide-based highly potent and selective pan-SIRT1/2/3 inhibitor harboring N
Li R; Yan L; Sun X; Zheng W
Bioorg Med Chem; 2020 Apr; 28(7):115356. PubMed ID: 32067892
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
Sakai T; Matsumoto Y; Ishikawa M; Sugita K; Hashimoto Y; Wakai N; Kitao A; Morishita E; Toyoshima C; Hayashi T; Akiyama T
Bioorg Med Chem; 2015 Jan; 23(2):328-39. PubMed ID: 25515955
[TBL] [Abstract][Full Text] [Related]
7. Assessment of SIRT2 Inhibitors in Mouse Models of Cancer.
Negrón Abril YL; Fernández I; Weiss RS
Methods Mol Biol; 2019; 1983():151-171. PubMed ID: 31087297
[TBL] [Abstract][Full Text] [Related]
8. A Glycoconjugated SIRT2 Inhibitor with Aqueous Solubility Allows Structure-Based Design of SIRT2 Inhibitors.
Hong JY; Price IR; Bai JJ; Lin H
ACS Chem Biol; 2019 Aug; 14(8):1802-1810. PubMed ID: 31373792
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of novel benzimidazole derivatives as sirtuin inhibitors with antitumor activities.
Yoon YK; Ali MA; Wei AC; Choon TS; Osman H; Parang K; Shirazi AN
Bioorg Med Chem; 2014 Jan; 22(2):703-10. PubMed ID: 24387981
[TBL] [Abstract][Full Text] [Related]
10. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer.
Hoffmann G; Breitenbücher F; Schuler M; Ehrenhofer-Murray AE
J Biol Chem; 2014 Feb; 289(8):5208-16. PubMed ID: 24379401
[TBL] [Abstract][Full Text] [Related]
11. Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity-Dependent Inhibition, and On-Target Anticancer Activities.
Spiegelman NA; Price IR; Jing H; Wang M; Yang M; Cao J; Hong JY; Zhang X; Aramsangtienchai P; Sadhukhan S; Lin H
ChemMedChem; 2018 Sep; 13(18):1890-1894. PubMed ID: 30058233
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Biological Evaluation of 8-Mercapto-3,7-Dihydro-1
Han H; Li C; Li M; Yang L; Zhao S; Wang Z; Liu H; Liu D
Molecules; 2020 Jun; 25(12):. PubMed ID: 32549218
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, in-vitro evaluation and molecular docking studies of novel indole derivatives as inhibitors of SIRT1 and SIRT2.
Manjula R; Gokhale N; Unni S; Deshmukh P; Reddyrajula R; Srinivas Bharath MM; Dalimba U; Padmanabhan B
Bioorg Chem; 2019 Nov; 92():103281. PubMed ID: 31561106
[TBL] [Abstract][Full Text] [Related]
14. Bivalent SIRT1 inhibitors.
Wang J; Zang W; Liu J; Zheng W
Bioorg Med Chem Lett; 2017 Jan; 27(2):180-186. PubMed ID: 27964881
[TBL] [Abstract][Full Text] [Related]
15. Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3.
Disch JS; Evindar G; Chiu CH; Blum CA; Dai H; Jin L; Schuman E; Lind KE; Belyanskaya SL; Deng J; Coppo F; Aquilani L; Graybill TL; Cuozzo JW; Lavu S; Mao C; Vlasuk GP; Perni RB
J Med Chem; 2013 May; 56(9):3666-79. PubMed ID: 23570514
[TBL] [Abstract][Full Text] [Related]
16. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients.
Grbesa I; Pajares MJ; Martínez-Terroba E; Agorreta J; Mikecin AM; Larráyoz M; Idoate MA; Gall-Troselj K; Pio R; Montuenga LM
PLoS One; 2015; 10(4):e0124670. PubMed ID: 25915617
[TBL] [Abstract][Full Text] [Related]
17. SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth.
Ma L; Maruwge W; Strambi A; D'Arcy P; Pellegrini P; Kis L; de Milito A; Lain S; Brodin B
Cell Death Dis; 2014 Oct; 5(10):e1483. PubMed ID: 25341037
[TBL] [Abstract][Full Text] [Related]
18. Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model.
Farooqi AS; Hong JY; Cao J; Lu X; Price IR; Zhao Q; Kosciuk T; Yang M; Bai JJ; Lin H
J Med Chem; 2019 Apr; 62(8):4131-4141. PubMed ID: 30986062
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of small molecule SIRT3-specific inhibitors as revealed by mass spectrometry.
Loharch S; Chhabra S; Kumar A; Swarup S; Parkesh R
Bioorg Chem; 2021 May; 110():104768. PubMed ID: 33676042
[TBL] [Abstract][Full Text] [Related]
20. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
Yang LL; Wang HL; Zhong L; Yuan C; Liu SY; Yu ZJ; Liu S; Yan YH; Wu C; Wang Y; Wang Z; Yu Y; Chen Q; Li GB
Eur J Med Chem; 2018 Jul; 155():806-823. PubMed ID: 29957526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
